The scale is moving. So why doesn’t the mirror agree?
If you’re on Ozempic, Wegovy, Mounjaro or Zepbound, there’s a good chance you’ve had some version of that thought. The first 20 pounds came off quickly. People noticed. Then the number stalled, the midsection stayed exactly where it was, and you started to wonder whether this is as good as it gets.
It isn’t. But to see why, you have to stop looking at your weight and start looking at what your weight is made of. Allow me to explain.
Weight Is the Wrong Scoreboard
Your body weight is 2 things added together: fat mass, and everything else. The “everything else” is lean mass: muscle, organs, bone and water. The scale can’t tell them apart. It gives you 1 number and leaves you to guess what moved.
2 men can both weigh 85 kg and look nothing alike. One is lean and strong. The other carries a soft midsection on a frame with very little muscle. Same number, completely different bodies, and completely different metabolic health.
For most senior leaders I speak to, the real goal was never a lower number. It’s a leaner body: less fat, more muscle, a physique that looks like the effort they put into everything else. That distinction matters more than ever, because GLP-1 drugs have become the default answer to weight, and they are extraordinarily good at moving the 1 number that matters least.
What the Drugs Actually Do
Let’s be fair to them first. They work. In the STEP 1 trial, adults with overweight or obesity on weekly semaglutide (the drug in Ozempic and Wegovy) lost an average of 14.9% of their body weight over 68 weeks, against 2.4% on placebo (1). That is a serious result, and for someone in a real health crisis it can be the difference between a manageable baseline and a dangerous one.
The engine behind it is simple. These drugs turn appetite down. You want less food, so you eat less food, so you lose weight. Nothing about that is magic. It’s a calorie deficit delivered by chemistry instead of willpower.
And that is exactly where the problem starts. A calorie deficit doesn’t choose what it takes. Left to its own devices, the body pays for the deficit with whatever tissue it can spare, and muscle is expensive tissue to keep.
Where the Weight Comes From
When researchers put people from STEP 1 through DXA body composition scans, total fat mass fell by 19.3%. Total lean mass fell by 9.7% (2). In a body composition sub-study of the tirzepatide trial (the drug in Mounjaro and Zepbound), fat mass fell by 33.9% and lean mass by 10.9%. Roughly 25% of all the weight lost was lean mass (3).
A 2024 review of GLP-1 therapies puts the wider picture plainly: depending on the study, lean mass has made up anywhere from about 15% to as much as 40 to 60% of the total weight lost (4).
To be clear on 2 points. First, lean mass is not only muscle; some of it is water and organ tissue. Second, fat fell faster than lean mass in these trials, so on paper body composition improved. Any aggressive diet costs some lean tissue. The drugs are not uniquely destructive.
But here’s what that means in practice. If nothing in your life is giving your body a reason to hold on to muscle, a meaningful slice of every kilo you lose is tissue you will want back. And after 40, you are already fighting the clock. Muscle mass and, even faster, strength decline with age; by the time men reach their 70s, strength is falling by around 3 to 4% a year (5).
Richard, a 69-year-old physician and former 3-time Ironman I spoke to on a sales call, put it in his own clinical terms: “I definitely have some sarcopenia now from the GLP drugs, and I haven’t done much to fix that.” Sarcopenia is the medical word for age-related muscle loss. He knew exactly what was happening, and he still hadn’t done anything about it.
Why Muscle Is the Asset You Can’t Afford to Sell
Muscle is not decoration. It is metabolically active tissue that burns energy at rest and in every activity you do. It is also where most of your blood sugar goes. In classic insulin clamp research, skeletal muscle accounted for more than 85% of total body glucose metabolism (6). Think of it as the body’s largest fuel tank, and the main thing standing between a big dinner and stored body fat.
Sell off muscle to make the scale move and you shrink the very system that keeps you lean. You end up lighter, but softer. The love handles and the midsection, the areas that made you want to lose weight in the first place, are often the last to shift.
Michael, a senior wealth manager in his late 60s I spoke to on a sales call, is a textbook case. On a GLP-1 since the previous August, he’d gone from 215 to 188 lb, then stalled for about 6 months. He was lifting weights 3 times a week and walking 3 miles a day. His body fat was still 36.8%. In his words: “I am stuck. Yes. I am stuck at 188.” The drug had done what the drug does. It got him lighter. It could not get him lean.
The Feedback Loop Nobody Mentions
There’s a second cost, and it rarely shows up in a trial.
For anyone who has ever been in good shape, progress runs on a loop. You eat well, so you train better. You train better, so you see and feel the result. The result makes the next good meal and the next session easy to choose. Round and round. That loop is the real motivation engine for driven people, far more than any willpower.
A GLP-1 can break it. Remove appetite and meals become a chore. Men describe eating as “drudgery” and the whole experience as feeling “very unnatural”. You lose track of what and when you’re eating, nutrition quietly collapses, training suffers, and with no visible progress there’s nothing to reinforce the next good decision.
This is why I think of these drugs in 2 very different categories. As damage control, for someone whose appetite and weight are truly out of control and who has never had a working structure, they can stop the bleeding. As a transformation tool, for someone with a history of discipline who simply lacks the right system, they solve a problem that person doesn’t have and create one they didn’t have before. For that person, appetite was never the constraint. The system was.
What Happens When You Stop
Most of the men I speak to who are on a GLP-1 share the same quiet worry. Tom, a 61-year-old banking executive, put it simply: “I’m a little concerned that that’s a crutch.” James, a 40-year-old investment manager: “I need to be convinced of the discipline that’s there to be able to come off of it.”
The data says their instinct is right. When STEP 1 participants stopped semaglutide and the trial’s lifestyle support, within a year they had regained 11.6 percentage points of the 17.3% they had lost, about 2 thirds of it, and most of the cardiometabolic improvements drifted back towards where they started (7). If the drug was doing the work, removing the drug removes the result.
The flip side is encouraging. In a 2021 trial, people who kept up regular exercise alongside a GLP-1 (liraglutide) maintained their weight loss best, and cut their body fat percentage by 3.9 points more than the placebo group (8). The drug got the weight down. The training is what made the body worth keeping.
5 Questions to Ask If You’re on a GLP-1 (or Considering One)
1) What is my weight actually made of?
Stop judging progress by the scale alone. Get a body composition scan, such as DXA, before you start or as soon as you can, then repeat it. If fat is falling and lean mass is holding, you’re getting leaner. If both are falling together, you’re just getting smaller.
2) What is telling my body to keep its muscle?
Muscle stays when it’s needed. Progressive resistance training is that signal. In older adults with obesity, adding resistance training to a calorie deficit reduced the loss of lean mass by about 93% compared with dieting alone (9). Walking, classes and cardio have their place, but they don’t send the same message.
3) Is protein still the anchor of every meal?
When appetite drops, protein is usually the first thing to go, because it’s the most filling food on the plate. The 2024 review flags exactly this: food preferences on these drugs can shift away from high-quality protein, and higher protein intake helps preserve lean mass (4). Eating less should mean eating less of everything else first.
4) Can I see my progress somewhere other than the scale?
Rebuild the feedback loop on purpose. Track your training: load, reps, strength over time. When you can see yourself getting stronger week to week, you have a reason to make the next good decision that doesn’t depend on appetite.
5) What will hold the result when the drug stops?
Plan the exit before you need it. Whether you come off in 6 months or 2 years, something has to replace the job the drug was doing. A system you understand, built around how you actually live, is the only thing that keeps the result once the chemistry is gone.
Lighter Is the Easy Part
A GLP-1 can get you lighter. It cannot get you lean, it cannot build muscle, and it cannot give you the understanding to keep the result on your own. For some people, damage control is the right first step. But damage control is not transformation, and the body you actually want is built, not suppressed into existence.
If you’re on one now and the scale has stalled, don’t change the dose or the diet first. Find out what your weight is made of. Then you’ll know what you’re really solving for.
If you take a GLP-1, or are thinking about starting or stopping one, make any change to it with your doctor.
Names of the men quoted in this article have been changed.
About the author
Cymron
A former investment banking director, I now coach senior leaders in their 40s and 50s to get lean, strong and healthy with a precise, science-based system built around a demanding life.
If this article describes where you are, you can apply to work with me HERE.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 2021. Link
- STEP 1 DXA body composition sub-study (semaglutide 2.4 mg, week 68). Poster 366, ABCD Diabetes Conference, October 2021. Link
- Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism, 2025. doi:10.1111/dom.16275. Link
- Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism, 2024. Link
- Mitchell WK, et al. Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength; a quantitative review. Frontiers in Physiology, 2012. Link
- DeFronzo RA, et al. Synergistic interaction between exercise and insulin on peripheral glucose uptake. Journal of Clinical Investigation, 1981. Link
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022. Link
- Lundgren JR, et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. New England Journal of Medicine, 2021. Link
- Sardeli AV, et al. Resistance Training Prevents Muscle Loss Induced by Caloric Restriction in Obese Elderly Individuals: A Systematic Review and Meta-Analysis. Nutrients, 2018. Link

What GLP-1 Drugs Do (and Don’t Do) to Your Body Composition" />